Clinical Trials for Other Solid Tumor

IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib with Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: This trial enrolls adults with advanced, EGFR-mutated non-squamous NSCLC—either after progression on prior EGFR TKI therapy or with persistent mutant ctDNA on front-line osimertinib—to receive a combination of osimertinib and carotuximab, a monoclonal antibody targeting endoglin (CD105) to inhibit tumor angiogenesis. Eligible patients may have stable or treated brain metastases and must have measurable disease and available tumor tissue or willingness to undergo biopsy.

ClinicalTrials.gov ID: NCT05401110

An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with untreated, unresectable, locally advanced or metastatic non-squamous NSCLC harboring HER2 exon 19 or 20 mutations and randomizes them to trastuzumab deruxtecan—an antibody-drug conjugate targeting HER2—or standard platinum chemotherapy with pembrolizumab and pemetrexed. Eligible patients must have ECOG performance status 0-1 and be candidates for systemic therapy.

ClinicalTrials.gov ID: NCT05048797

Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with stage IV or recurrent NSCLC harboring EGFR, ALK, ROS1, or HER2 alterations, who have progressed after appropriate targeted and systemic therapy (excluding prior PD-1/PD-L1 inhibitors). Patients receive CD40L-augmented tumor-infiltrating lymphocytes (TILs), which are designed to enhance T-cell activation, in combination with nivolumab following lymphodepleting chemotherapy and interleukin-2 support.

ClinicalTrials.gov ID: NCT05681780

Phase II Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-Small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with metastatic or unresectable NSCLC and ECOG performance status 0-2 (excluding those with actionable mutations or significant comorbidities) to receive standard first-line chemoimmunotherapy regimens, including pembrolizumab (anti-PD-1 antibody) plus histology- and PD-L1–guided platinum-doublet chemotherapy, comparing efficacy and safety outcomes between PS 2 and PS 0-1 patients.

ClinicalTrials.gov ID: NCT04253964

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Advanced KRAS Mutated Non-Small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial is enrolling patients with unresectable stage III/IV non-small cell lung cancer harboring specific KRAS mutations (G12C, G12V, G12D, G12A, G13D, or G12R) who have not had prior therapy for advanced disease, to evaluate a KRAS-targeted long peptide vaccine (designed to elicit immune responses against mutant KRAS) combined with poly-ICLC adjuvant, nivolumab (PD-1 inhibitor), and ipilimumab (CTLA-4 inhibitor). Key exclusions include prior immunotherapy, active autoimmune disease, and untreated or symptomatic brain metastases.

ClinicalTrials.gov ID: NCT05254184

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls treatment-naïve adults with metastatic, sensitizing EGFR-mutant (non-exon 20 insertion) non-squamous NSCLC (stage IIIB-IV/recurrent, ECOG 0-2) to compare osimertinib (a third-generation EGFR TKI) alone versus in combination with bevacizumab, an anti-VEGF antibody, as first-line therapy. Patients must be eligible for anti-VEGF treatment and have measurable disease.

ClinicalTrials.gov ID: NCT04181060

PROMISE-005: A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Breast or Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with oligometastatic breast cancer (all subtypes) or non-small cell lung cancer (1-5 measurable metastases) who are randomized to receive either standard systemic therapy or standard systemic therapy plus stereotactic body radiotherapy (SBRT) to all metastatic sites. Eligible patients may have newly diagnosed or stable metastatic disease and must have lesions suitable for SBRT or local therapy.

ClinicalTrials.gov ID: NCT03808337

Phase II, Single-Arm Study Of Carboplatin, Weekly Taxane, And Ramucirumab In Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progressive Disease On Maintenance Pemetrexed And/Or Pembrolizumab

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Enrolling adults with advanced non-squamous NSCLC and ECOG 0-1 whose disease progressed after maintenance pemetrexed and/or pembrolizumab, this trial investigates carboplatin, weekly paclitaxel, and ramucirumab (a VEGFR-2 inhibitor monoclonal antibody), excluding patients with targetable driver mutations or untreated brain metastases.

ClinicalTrials.gov ID: NCT04332367

A Phase Ib Dose De-Escalation Study of All-Trans Retinoic Acid (ATRA) and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with advanced (recurrent or metastatic) NSCLC of any histology who have progressed after standard therapies, including those previously treated with PD-1/PD-L1 inhibitors and those with stable brain metastases. Patients receive oral all-trans retinoic acid (ATRA, an immunomodulator that reduces myeloid-derived suppressor cells) in combination with intravenous atezolizumab (anti-PD-L1 checkpoint inhibitor).

ClinicalTrials.gov ID: NCT04919369

Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls immunotherapy-naive patients with stage IV or oligometastatic NSCLC (excluding those with EGFR or ALK alterations if adenocarcinoma), who may have had prior chemotherapy or targeted therapy, and randomizes those with non-progressive disease after induction nivolumab (PD-1 inhibitor) plus ipilimumab (CTLA-4 inhibitor) to either continue immunotherapy alone or receive local consolidation therapy (surgery, radiation, or ablation) to up to 3 lesions followed by continued immunotherapy. Patients with previously treated or asymptomatic small brain metastases are eligible.

ClinicalTrials.gov ID: NCT03391869